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Patients with Brugada syndrome (BrS) not uncommonly suffer from recurrent and recalcitrant
ventricular ﬁbrillation episodes, the so-called ‘‘electrical storm’’ which is malignant and potentially
lethal event. While electrical storm in BrS is a therapeutic challenge, fortunately there are effective
therapeutic solutions which must be compulsory applied: Elimination of precipitating factors,
isoproterenol and oral quinidine are the ﬁrst 2 therapeutic steps that one must urgently commenced.
And if this measure should fail, ablation of the triggering ventricular premature beats and/or substrate
ablation at the anterior aspect of the right ventricular outﬂow tract should be performed.
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Two decades ago, Pedro and Joseph Brugada described a group
of 8 patients with a normal heart who suffered ventricular
ﬁbrillation (VF) or sudden cardiac death and had an abnormal
electrocardiogram (ECG) of coved type ST elevation over the right
precordial leads [1]. It was acknowledged instantly as the Brugadart Rhythm Society. Published by E
016/j.joa.2013.03.001
anee).syndrome (BrS), which has also been linked with sudden unex-
pected death syndrome (SUDS) that usually occurs at night in
young Southeast Asian men with a normal heart [2,3]. BrS now is
well recognized as a common autosomal dominant inherited
arrhythmia disorder with gene mutations that are predominantly
conﬁned to the SCN5A gene, which encodes for a-subunit of
sodium channel, causing loss of INa [3–6].
Treatment of BrS patients is a signiﬁcant challenge because there
are limited treatment options, and an implantable cardioverter–
deﬁbrillator (ICD) is the only choice for high-risk BrS patients (i.e.,
those who had aborted sudden cardiac death or had previous VF
episodes) [7–10]. Unfortunately, even though ICDs are effective atlsevier B.V. All rights reserved.
Fig. 1. An example of recurrent VF episodes in a patient with type 1 Brugada ECG pattern who presented with cardiac arrest associated with high temperature and
hypokalemia. The patient had frequent PVCs triggering VF episodes 5 times over the span of 3 h on February 25, 2004. Note the identical pattern of VF episodes that were
triggered by short-coupling PVCs.
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occurrence. Thus, when some BrS patients experience frequent
recurrences of VF episodes necessitating frequent ICD discharges,
the so-called ‘‘electrical storm’’ (ES), physicians face the daunting
task of suppressing such VF episodes. Fortunately, in recent years,
we have learned a great deal more about the syndrome and have
therapeutic advances that enable us to treat BrS patients with ES
much more effectively than a decade ago. Our review herewith will
discuss these advances and how to treat ES in BrS patients most
effectively.2. Deﬁnition and incidence of electrical storm
ES is deﬁned as three or more episodes of VF per day recorded by
the ICD interrogation or documented in the recording in the intensive
care unit (ICU) (Fig. 1). The true incidence of ES in the BrS is difﬁcult
to ascertain. Thus far, most of the reports of ES have been case reports
or studies with a very small number of patients. The incidence of ES
in our BrS population in Thailand is 5–7% in symptomatic patients,
but none in our asymptomatic BrS population.3. Mechanisms of ventricular ﬁbrillation/electrical storm
in the Brugada syndrome patients
One of the most consistent features of BrS is that premature
ventricular contraction (PVC), which triggers VF, is almost always
short-coupling [3,4]. An interesting phenomenon is that many of
the VF episodes in BrS patients are self-terminating, contradicting
the conventional wisdom that VF episodes are equivalent to
death. Indeed, after experiencing the growing numbers of patients
with this syndrome, we have learned that VF in patients with a
structurally normal heart, unlike those with ischemic heart
disease, often spontaneously reverts back to sinus rhythm [3,4].Two questions arise: (1) Why are some VF episodes sustained
and frequently recurrent, causing ES and leading to sudden death
or cardiac arrests? (2) What are the underlying electrophysiologic
mechanisms and predisposing and precipitating factors that
modulate the substrate, resulting in perpetuation of the VF?
While answers to these questions remain elusive, some new
information in recent years has emerged, which may partially
help to explain the pathogenesis of VF occurrences.
In recent years, there has been a well-recognized debate of the
pathophysiologic and electrophysiologic mechanisms underlying
BrS: repolarization vs. depolarization [11]. Shortly after the
syndrome was introduced, Antzelevitch and colleagues proposed
the repolarization theory as the electrophysiologic abnormalities
of the BrS that were largely based on their arterially perfused
wedge preparation of the canine right ventricle (RV) [12]. They
found that a combination of sodium channel blockers and
acetylcholine caused a loss of the action potential (AP) dome in
RV epicardium, but not in RV endocardium, and created a
transmural voltage gradient. And when the wedge preparation
was exposed to these 2 drugs, this area then developed a notch
and dome appearance of the epicardium AP, leading to a coved
type ST-segment elevation in the right precordial leads. The RV
epicardium is well known to have abundant Ito, which in turn
makes this area more conducive to the accentuation of the AP
dome and shortening of AP. If the loss of the AP dome is further
accentuated, then it causes the marked shortening of the epicar-
dial AP in certain regions, causing pronounced heterogeneity of
transmembrane voltage potentials and, in turn, causing phase
2 reentry and triggered VF.
The clinical relevance to support this theory is the ﬁndings
that there is a good correlation between a long RR interval and the
magnitude of ST-elevation over the right precordial leads. Matsuo
et al. presented a case report of a patient with BrS in whom
12-lead ECGs were recorded just before and after an episode of VF
[13]. They demonstrated a progressive elevation of both the RS–T
segment and J waves just preceding and following the VF, and a
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and the preceding R–R intervals during atrial ﬁbrillation. Simi-
larly, Mizumaki et al. showed that ST elevation over the right
precordial leads was augmented during bradycardia to a similar
extent in both symptomatic and asymptomatic patients [14].
These ﬁndings along with the evidence that isoproterenol attenu-
ates ST-elevation in BrS suggest that the mechanism underlying a
pause dependent augmentation of the ST elevation in BrS may be
due to an increase in Ito after prolonged RR interval—in turn
supporting repolarization disorder.
Kurita et al. presented a case report in which monophasic AP
recordings from epicardium and endocardium were performed
simultaneously in the BrS patient [15]. The transmembrane gradient
of AP between the epicardium and endocardium were observed;
however, the authors did not ﬁnd the shortening of the epicardial
AP. Perhaps this observational study shows that quinidine, a strong
Ito blocker, is effective in treating BrS patients also indirect evidence
that supports the repolarization theory [16]. While the repolariza-
tion theory enjoyed its popularity early on, the lack of more strong
clinically relevant ﬁndings to convincingly support the concept led
to the other theory, depolarization disorder.
The depolarization disorder hypothesis considers that conduction
delay, particularly in the RV outﬂow tract (RVOT), plays a role in the
pathogenesis of BrS. Using an electrical guidewire to record an
epicardial electrogram from a conus branch of the right coronary
artery, Negase et al. were the ﬁrst to show abnormal electrograms
characterized by late potential after QRS, which were recorded from
the free wall of the RVOT epicardium in the BrS patients [17]. Their
ﬁndings suggest conduction delay in the RVOT epicardium. Coronel
et al. reported their ﬁndings from the explanted heart of a BrS patient
who had SCN5A mutation with medically-treated failure VF storms,
necessitating heart transplantation surgery [18]. The explanted heart
showed no evidence of repolarization abnormality; instead, they
found evidence of interstitial ﬁbrosis causing conduction delay. The
RVOT endocardium showed activation slowing, and was the origin of
VF without a transmural repolarization gradient. The investigators
then proposed the depolarization hypothesis, which contends that in
BrS, the RVOT depolarizes last after the rest of the ventricular
myocardium has completely depolarized [19]. As a result, the delay
in the AP of the RVOT causes the electrical gradient from the more
positive RV to RVOT, leading to the ST-elevation of the right
precordial leads similar to the situation of a myocardial injury at
the RVOT and as the RVOT depolarizes later (during repolarization of
the RV), this gradient is reversed and the net current ﬂows toward the
RV, resulting in a negative T wave in the same right precordial leads.Fig. 2. A typical low-voltage fractionated late potential recorded at the anterior aspThe experiment from the same group in this explanted heart also
showed that this site is the arrhythmogenic site during programmed
stimulation-induced VF. Frustaci et al. also reported the biopsy
ﬁndings showing ﬁbrosis in patients with the Brugada phenotype
[20]. And there are a number of clinical studies showing that the
delayed activation of the RVOT in BrS patients indeed occurred
[21–27]. Regardless of which theory is correct, it becomes quite clear
from the preceding studies as well as from the study by Moriata et al.
[28], that the RVOT is the likely arrhythmogenic substrate site of
the BrS.
Our group then carried out a study to determine the substrate
sites and arrhythmogenic mechanisms of the BrS [29]. We found
that all our BrS patients had abnormal low voltage, fractionated
late potentials exclusively clustering in the anterior aspect of the
RVOT epicardium and not seen anywhere else, and RVOT endo-
cardium or left ventricular (LV) epicardium. Fig. 2 shows an
example of low-voltage fractionated electrograms recorded from
the anterior RVOT epicardium of a patient who presented with ES.
Ablation at this area normalized the Brugada ECG pattern and
prevented recurrent VF episodes. Similar observations were found
in all our study patients, and these ﬁndings clearly provide the
strongest clinical evidence that the delayed depolarization at the
anterior aspect of the RVOT is the most likely underlying electro-
physiologic mechanism underlying BrS (see more discussion
below). Although it is quite apparent that depolarization disorder
is likely to be the main mechanism underlying the BrS, one has to
be mindful that repolarization abnormality could contribute to
the arrhythmogenesis of the BrS patients, along with genetic
mutations of ionic channel and other precipitating factors.
Genetic mutation in BrS was ﬁrst described by Chen et al., who
reported the ﬁrst mutation linked to BrS in the SCN5A gene, which
encodes for the a-subunit of the sodium channel [30]. Since then,
4100 SCN5A mutations have been discovered in BrS patients, and
they are the most common type found in 11–28% of BrS probands;
however, the genetics of BrS have become heterogeneous. In addition
to the SCN5A mutations, more mutations are found in gene encoding
protein of potassium and calcium channels. These genetic ﬁndings in
and the pharmacological features of BrS are generally considered
favorable evidence for the repolarization theory. However, in struc-
tural discontinuous myocardium, AP propagation is determined by
the tissue architecture itself which is abnormal in BrS, as evidenced
by the late fractionated potential in the anterior RVOT epicardium
and by the ionic current available for propagation. The latter is more
or less determined by the APmorphology, which in turn is modulated
by INa, ICaL and Ito. A decrease in INa (commonly seen in SCN5Aect of the RVOT in a patient with the typical type 1 Brugada ECG pattern in V2.
Fig. 3. Proposed pathophysiologic mechanisms of BrS with respect to predisposing factors.
Fig. 4. Algorithm of a management approach for electrical storm associated with
the Brugada syndrome.
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IKATP, modify the action morphology in such a way that safety of
conduction is decreased (i.e., potentially leading to conduction slow-
ing or conduction block in structural discontinuous myocardium or at
Purkinje-ventricular muscle boundaries). All of these possibilities are
linked to genetic variants associated with BrS, and some of them, in
particular the amplitude of ICaL, are sensitive to changes in auto-
nomic tone. Similarly, pharmacologic interventions that block Ito or
increase ICaL, respectively, quinidine and isoproterenol, are expected
to exert the opposite effect and improve safety of conduction. Indeed,
both drugs are known to attenuate the Brugada ECG pattern and
suppress the associated arrhythmias.
Fig. 3 shows the possible pathophysiologic mechanisms under-
lying BrS and their modulating and precipitating factors. BrS patients
had arrhythmogenic substrates displaying as late fractionated low-
voltage potential in the anterior RVOT epicardium, which causes type
I Brugada ECG pattern or could be accentuated or unmasked bysodium channel blocker (i.e., ajmaline, procainamide, ﬂecainide, etc.),
febrile illness, vagotonic agents, a-adrenergic agonists, b-adrenergic
blockers, tricyclic or tetracyclic antidepressants, or ﬁrst generation
antihistaminies (dimenhydrinate).
In the presence of SCN5A mutation that results in loss of INa,
BrS patients not only could have more prominent ECG abnorm-
ality, but also develop short-coupling PVCs that could trigger
VT/VF. In the presence of predisposing factors such as an altered
autonomic nervous system, fever, or hypokalemia, VF could
become sustained and occur frequently.4. Algorithm of treatment approach in Brugada syndrome
patients with electrical storm
Fig. 4 shows the ﬂow diagram of how we treat BrS patients with
ES. Patients are admitted to the ICU and should be well sedated, and
some may require general anesthesia with endotracheal intubation.
The patients are evaluated to determine if there are precipitating
factors to be eliminated or treated. In the acute phase of ES when
patients continue to have recurrent VF episodes, Steps 1 and 2, as
described below, should be carrried out simultaneously.
4.1. Step 1: elimination of precipitating factors
Precipitating factors for VF in the BrS, as shown in Fig. 2, often
are present during ES, and if they were eliminated, ES often
subsided. Fig. 4 shows an example of successful ES treatment of
the same patient as in Fig. 1, by treating fever and replacing
potassium. However, if one encounters BrS patients who continue
to have recurrent VF despite having no obvious precipitating
factors or have been well treated, then one has to go to the next
step using pharmacological treatment.
4.2. Step 2: pharmacological treatment
Only a few drugs that been found to be effective in treating ES
in BrS patients, and most published data came from case reports
and studies with a small number of patients [31–35]. Never-
theless, the following drugs are found by most investigators to be
useful in treating ES.
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Isoproterenol, well known to normalize the Brugada ECG pattern
by increasing ICaL, is found to be effective in acute treatment of ES.
Ohgo et al. found that isoproterenol (0.00370.003 mg/kg/min), by
raising heart rate by 20%, completely suppressed ES in all 5 BrS
patients [31]. After this acute treatment, the investigators prescribed
denopamine (an aþb adrenergic agonist) at a dose of 30 mg/day,
which was found to be effective in 3 of the 5 patients at long-term
follow-up; however, 2 of the remaining patients required a con-
comitant treatment of quinidine (see discussion below) during
chronic treatment. These ﬁndings and reports by others indicate
that isoproterenol is the drug of choice during the acute phase of ES
in BrS patients.
Cilostazol, an oral phosphodiesterase inhibitor, has also been
shown to be efﬁcient in preventing recurrent VF in BrS patients
[31,36]. Drugs that decreased the vagal tone (by decreasing IKAch
and increasing ICaL), such as atropine, may be beneﬁcial by
increasing the heart rate and in turn decreasing Ito. However,
atropine infusion alone is not quite as effective as isoproterenolFig. 5. Successful treatment of electrical storm by treating fever, potassium
repletion, and amiodarone for the same Brugada syndrome patient as in Fig. 1.
Fig. 6. A composite picture of the CARTO-merge maps of a Brugada syndrome patient w
the electroanatomic maps of the right ventricular outﬂow tract (RVOT) epicardium.
abnormal prolonged duration of the ventricular electrograms in the anterior RVOT a
(4160 ms) during sinus rhythm. The voltage map, shown in the middle, is the same
voltage in red and high voltage in purple. The right inset displays the electrograms recor
RVOT epicardium (arrow); (refer to the text for details). Red dots represent ablation p
electrograms are recorded from the anterior aspect of the RVOT epicardium. Note that t
voltage (o1 mV). The bipolar electrogram recorded from this site shows the electrogra
delayed depolarization beyond the end of the lead II-QRS complex (160 ms). Bi-DIST¼
with permission from .
Nademanee et al. [29]infusion. Clearly, in the presence of acute ES, isoproterenol infusion,
along with the Step 1 recommendation to eliminate or correct the
precipitating factors, should be commenced simultaneously.4.2.2. Quinidine and other antiarrhythmic drugs
Bellhassen et al. demonstrated that quinidine is an effective drug
for treatment of ventricular arrhythmias associated with BrS.
Although the drug is a class IA antiarrhythmic agent, it is also a
potent Ito blocker [16]. Bellhassen and colleagues found that quinidine
bisulfate at a mean dose of 1.5 g daily prevented VF inducibility in
88% of patients and was associated with no recurrence of arrhythmia
with a mean follow-up of 56 months. Others also have found that the
drug is quite useful in BrS patients with ES. However, quinidine at the
high dose is associated with a high incidence of side effects
(approximately 36%): gastrointestinal symptoms, liver dysfunction,
thrombocytopenia, allergic reaction, and QT prolongation are not
uncommon. Marquez et al., reported a retrospective study of an
efﬁcacy of low-dose quinidine (r600mg daily) in 6 BrS patients with
VF episodes necessitating ICD discharges (including 4 patients with
ES). They found that low-dose quinidine prevented VF recurrence in
all 6 patients in their series [37]. The investigators also combined
their patients to those reported in the literature, from which they
found 14 additional BrS patients treated with the low-dose quinidine.
After combing both the literature review and their cases, they found
that low-dose quinidine is effective in preventing VF recurrences up
to 85%, and is well tolerated. However, in many parts of the world,
unfortunately, quinidine is not available, as the pharmaceutical
companies have ceased its production due to low proﬁt [38].
Bepridil, a class III drug with Ito blocking properties, is reported
to be effective in treating BrS patients with frequent VF recur-
rences, but the drug is only available in Japan [31,39]. Amiodar-
one has not been found to be reliably effective. However, it is the
only drug that could be used in Thailand with variable success, as
shown in the patient in Fig. 5.ith electrical storm shows the cardiac computed tomography that is merged with
The double annotation map (A2–A1), shown on the left, illustrates the scale of
s displayed in the color-coded area; the purple represents the longest duration
as the A2–A1 map, but is displayed differently, with the color-coded area of low
ded from the NaviStar-ThermoCool catheter at the site of the anterior aspect of the
oints. The voltage map and the representative tracing of the bipolar and unipolar
he duration of the electrograms in this area is quite prolonged (4150 ms) and low
m is low voltage (0.84 mV), fractionated, and has prolonged duration (183 ms) and
bipolar distal; Bi-PROX¼bipolar proximal; Uni-DIST¼unipolar distal. Reproduced
Fig. 7. A left lateral view of the right ventricular outﬂow tract (RVOT) displays the difference in ventricular electrograms between the endocardial and epicardial site of the
anterior RVOT of the same patient as in Fig. 6. The left and right insets display bipolar and unipolar electrograms recorded from the epicardium and endocardium from the
same site of the RVOT, respectively. Bi-DIST¼bipolar distal; Bi-PROX¼bipolar proximal; Uni-DIST¼unipolar distal; Uni-PROX¼unipolar proximal. Reproduced with
permission from .
Nademanee et al. [29]
Fig. 8. Comparison of ventricular electrograms recorded from different sites in both the left ventricle (LV) and right ventricle (RV) of the same patient as in Figs. 6 and 7.
Reproduced with permission from .
Nademanee et al. [29]
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4.3.1. Ablation of the VF triggers
Haı¨ssaguerre et al. was the ﬁrst to report the non-pharmacologic
approach using mapping and ablating PVCs that triggered VF. They
found PVCs that triggered VF emanating from the RVOT in 2 patients,and from the anterior RV Purkinje network in 1 patient [40]. After
ablations of these triggering PVCs, all 3 patients had no VF
recurrences over a 1.5-year follow-up period. Since then, there have
been a few more case reports with similar approaches and results
[41,42]. Unfortunately, most of the BrS patients rarely have PVCs
frequent enough to be mapped, even during the ES period. The
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nature and poses a problem for anyone attempting to map these
triggers, and in turn, limited this approach from being practical in
treating many BrS patients with ES, leading to the search of BrS
substrates as target sites for catheter ablation.
4.3.2. Substrate ablation
As described earlier, we recently studied 9 symptomatic
patients with BrS (all male; mean age 39 years) who had multiple
recurrent VF episodes (471.5) per month, necessitating multiple
ICD shocks. Using CARTO Electroanatomical mapping (Biosense
Webster, Diamond Bar, CA USA) of the RV both endocardially and
epicardially and epicardial mapping of the LV were performed in
all patients during sinus rhythm [29]. All patients had typical type
1 Brugada ECG pattern and inducible VT/VF.
Fig. 6 shows an example of our CARTO map in a BrS patient with
ES showing abnormal ventricular electrograms recorded in the area
of the anterior RVOT epicardium, as evidenced by abnormal pro-
longed ventricular electrograms (4150 ms), markedly delayed
depolarization, as shown by the late potential that continued to
depolarize beyond the QRS complex (4160 ms), and very low-
voltage fractionated electrograms. These abnormal electrograms are
exclusively localized in a cluster over the anterior RVOT epicardium
and are not seen anywhere else in the right or left ventricle
(Figs. 7 and 8). As shown in Fig. 7, the endocardial site (arrow)
displays a single potential of 2.09 mV, with a duration of 58 ms, and
did not extend beyond the QRS compared to the epicardial counter-
part that showed low-voltage late potential (0.48 mV), with a
duration of 236 ms with late potential extended beyond QRS.
Fig. 8 shows epicardial electrograms recorded from various
sites of the epicardium in both the LV and RV epicardium. Note
that abnormal fractionated electrograms and double potential
electrograms are only localized in the anterior aspect of the RVOT
epicardium.
We found that all other patients in this study also had identical
substrates at the same area of the anterior RVOT epicardium,
which is characterized by abnormal low-voltage fractionated
ventricular electrograms (o1 mV) that have a markedly delayed
conduction time after QRS complex on the surface ECG (4100 ms),
and a markedly prolonged duration (4130 ms). Ablation at these
sites rendered VT/VF non-inducible in 78% of our patients, and
normalization of the Brugada ECG pattern in 89% of our patients.
Thus, we have identiﬁed and shown that anterior RVOT epicardium
is the arrhythmogenic substrate site for our BrS patients. We have
now performed ablations in 20 BrS patients with frequent ICD
discharges; 3 patients required a second ablation, but there were
no complications. Long-term outcomes (median 32 months) were
excellent, with no recurrent VT/VF in all patients off medication.
Long-term outcomes (median 32 months) were excellent, with no
recurrent VT/VF in all patients off medication. Based on these
ﬁndings, our study provides major clinical implication that has
therapeutic value for BrS patients with ES: We now can ﬁnd the
arrhythmogenic substrate that serves very well as target sites for
catheter ablation, and thus can expect a good clinical outcome.
Further studies clearly need to be done to assess values and
limitations of catheter ablation in patients with BrS with frequent
ICS shocks.5. Conclusions
The past two decades since BrS was ﬁrst reported has wit-
nessed major progress toward understanding pathophysiology of
the syndrome. We now have more therapeutic advances to deal
with recurrent VF storms necessitating multiple successive ICD
shocks, the electrical storm. Elimination of precipitating factors,quinidine and catheter ablation of epicardial substrate in ES cases
are our best choice of treatment that is likely to be effective and
not only ameliorate patient symptoms but prevent untimely
death as well. In other words, we are now well equipped with
both knowledge and tools to help our BrS patients ride out the
electrical storm safely.Conﬂict of interest
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